

CD80 antibody [2D10.4] (APC)

Cat. No. GTX01487-07

Host	Mouse
Clonality	Monoclonal
Isotype	lgG1
Applications	FCM
Reactivity	Human, Rhesus Monkey

References (3)
Package
100 test

PRODUCT

Summary

The 2D10.4 antibody reacts with human CD80, a 60 kDa glycoprotein that is a member of the lg superfamily. CD80, also known as B7-1, is a ligand for the T cell receptors CD28 and CTLA-4 (CD152). Along with CD86, CD80 plays a major role in regulating the activation of T cells. CD80 is expressed by activated antigen presenting cells including B cells, macrophages, and dendritic cells. Activated T cells have also been reported to express CD80.

Applications

Application Note

*Optimal dilutions/concentrations should be determined by the researcher.

Suggested dilution Recomm	nended dilution
FCM 0.5 μg (5	$_{5}$ μl) for 10^{5} - 10^{8} cells in 100 μl sample per test

Not tested in other applications.


Properties	
Form	Liquid
Buffer	10mM NaH₂PO₄, 150mM NaCl, 0.1% Gelatin
Preservative	0.09% Sodium azide
Storage	Store as concentrated solution. Centrifuge briefly prior to opening vial. Store at 4°C. DO NOT FREEZE. Protect from light.
Concentration	0.1 mg/ml (Please refer to the vial label for the specific concentration.)
Purification	Purified by affinity chromatography From tissue culture supernatant
Conjugation	Allophycocyanin (APC) Wavelength
Note	For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
	Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.



For full product information, images and publications, please visit our <u>website</u>.

Date 2025 / 12 / 27 Page 1 of 2

DATA IMAGES



GTX01487-07 FCM Image

FACS analysis of Daudi cells using GTX01487-07 CD80 antibody [2D10.4] (APC).

Solid lone: primary antibody

Dashed line: isotype control
antibody amount: 0.5 µg (5 µl)



For full product information, images and publications, please visit our <u>website</u>.

Date 2025 / 12 / 27 Page 2 of 2